A 68-year-old with T2DM, A1c 8.3%, ASCVD, CKD, and obesity is on metformin and SGLT2 inhibitor. Which additional therapy has proven MACE reduction and...

Question

A 68-year-old with T2DM, A1c 8.3%, ASCVD, CKD, and obesity is on metformin and SGLT2 inhibitor. Which additional therapy has proven MACE reduction and weight loss?

Accepted Answer

GLP-1 receptor agonist

Answer

DPP-4 inhibitor

Answer

Sulfonylurea

Answer

Basal insulin

Answer

Meglitinide

us-abfm MCQ (SBA): Type 2 Diabetes-Comprehensive CV Therapy

A 68-year-old with T2DM, A1c 8.3%, ASCVD, CKD, and obesity is on metformin and SGLT2 inhibitor. Which additional therapy has proven MACE reduction and weight loss?